Citadel Advisors
ZNTL icon

Citadel Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Citadel Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
2,298,403
+566,320
+33% +$2.26M ﹤0.01% 3410
2026
Q1 		$4.05M Sell
1,732,083
-232,172
-12% -$600K ﹤0.01% 4691
2025
Q4 		$2.65M Sell
1,964,255
-113,035
-5% -$165K ﹤0.01% 5401
2025
Q3 		$3.14M Buy
2,077,290
+1,614,950
+349% +$2.42M ﹤0.01% 5231
2025
Q2 		$536K Buy
462,340
+391,282
+551% +$516K ﹤0.01% 8460
2025
Q1 		$113K Sell
71,058
-3,145,669
-98% -$6.78M ﹤0.01% 11293
2024
Q4 		$9.75M Buy
3,216,727
+499,206
+18% +$1.64M ﹤0.01% 3019
2024
Q3 		$10M Sell
2,717,521
-1,785,392
-40% -$6.49M ﹤0.01% 2893
2024
Q2 		$18.4M Buy
4,502,913
+650,484
+17% +$7.26M ﹤0.01% 2079
2024
Q1 		$60.7M Buy
3,852,429
+170,647
+5% +$2.35M 0.01% 1055
2023
Q4 		$55.8M Buy
3,681,782
+1,526,431
+71% +$22.3M 0.01% 1094
2023
Q3 		$43.2M Buy
2,155,351
+26,055
+1% +$661K 0.01% 1184
2023
Q2 		$60.1M Buy
2,129,296
+799,303
+60% +$19.2M 0.01% 916
2023
Q1 		$22.9M Buy
1,329,993
+692,273
+109% +$14M 0.01% 1796
2022
Q4 		$12.8M Buy
637,720
+84,919
+15% +$1.83M ﹤0.01% 2476
2022
Q3 		$12M Sell
552,801
-209,894
-28% -$5.74M ﹤0.01% 2503
2022
Q2 		$21.4M Buy
762,695
+251,670
+49% +$6.67M 0.01% 1778
2022
Q1 		$23.6M Sell
511,025
-88,611
-15% -$4.78M ﹤0.01% 1797
2021
Q4 		$50.4M Sell
599,636
-503,157
-46% -$38.9M 0.01% 1159
2021
Q3 		$73.5M Sell
1,102,793
-130,187
-11% -$7.51M 0.02% 849
2021
Q2 		$65.6M Buy
1,232,980
+177,591
+17% +$9.51M 0.01% 929
2021
Q1 		$45.8M Sell
1,055,389
-448,481
-30% -$19.3M 0.01% 1110
2020
Q4 		$78.1M Sell
1,503,870
-185,764
-11% -$8.38M 0.02% 681
2020
Q3 		$55.2M Buy
1,689,634
+128,947
+8% +$4.51M 0.02% 799
2020
Q2 		$74.9M Buy
+1,560,687
New +$59.9M 0.03% 550

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors's ZNTL Position: Q2 2026 in Review

Citadel Advisors increased its Zentalis Pharmaceuticals (ZNTL) stake by 33% in Q2 2026, buying an estimated $2.26M and bringing the position to 2,298,403 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

Citadel Advisors first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $78.1M in Q4 2020. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Citadel Advisors held 2,298,403 shares of Zentalis Pharmaceuticals worth $11.1M as of Q2 2026.
  • Citadel Advisors bought 566,320 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.26M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3410 holding.
  • Citadel Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Citadel Advisors's Zentalis Pharmaceuticals position peaked at $78.1M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.